S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
3 Value Stocks Too Small For Buffett’s Portfolio
Stock market today: Asian shares are mostly higher after another set of Wall St records
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
How major US stock indexes fared Thursday, 3/28/2024
MillerKnoll, Chemours fall; Verint Systems, RH rise, Thursday, 3/28/2024
Mark Zuckerberg Says This CEO Is the 'Taylor Swift of Tech'
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
3 Value Stocks Too Small For Buffett’s Portfolio
Stock market today: Asian shares are mostly higher after another set of Wall St records
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
How major US stock indexes fared Thursday, 3/28/2024
MillerKnoll, Chemours fall; Verint Systems, RH rise, Thursday, 3/28/2024
Mark Zuckerberg Says This CEO Is the 'Taylor Swift of Tech'
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
3 Value Stocks Too Small For Buffett’s Portfolio
Stock market today: Asian shares are mostly higher after another set of Wall St records
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
How major US stock indexes fared Thursday, 3/28/2024
MillerKnoll, Chemours fall; Verint Systems, RH rise, Thursday, 3/28/2024
Mark Zuckerberg Says This CEO Is the 'Taylor Swift of Tech'
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
3 Value Stocks Too Small For Buffett’s Portfolio
Stock market today: Asian shares are mostly higher after another set of Wall St records
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
How major US stock indexes fared Thursday, 3/28/2024
MillerKnoll, Chemours fall; Verint Systems, RH rise, Thursday, 3/28/2024
Mark Zuckerberg Says This CEO Is the 'Taylor Swift of Tech'
NASDAQ:XFOR

X4 Pharmaceuticals (XFOR) Stock Price, News & Analysis

$1.39
-0.02 (-1.42%)
(As of 03/28/2024 ET)
Today's Range
$1.30
$1.43
50-Day Range
$0.72
$1.46
52-Week Range
$0.57
$2.58
Volume
4.35 million shs
Average Volume
3.37 million shs
Market Capitalization
$233.44 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$3.00

X4 Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
115.8% Upside
$3.00 Price Target
Short Interest
Bearish
8.47% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.85
Upright™ Environmental Score
News Sentiment
0.56mentions of X4 Pharmaceuticals in the last 14 days
Based on 15 Articles This Week
Insider Trading
Selling Shares
$170,428 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.52) to ($0.44) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.27 out of 5 stars

Medical Sector

166th out of 939 stocks

Biological Products, Except Diagnostic Industry

21st out of 158 stocks

XFOR stock logo

About X4 Pharmaceuticals Stock (NASDAQ:XFOR)

X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia. The company is also developing X4P-003, a CXCR4 antagonist for the treatment of CXCR4 dependent disorders and primary immunodeficiencies; and X4P-002, a CXCR4 antagonist for the treatment of blood-brain barrier diseases. It has a license agreement with Abbisko Therapeutics Co Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company is headquartered in Boston, Massachusetts.

XFOR Stock Price History

XFOR Stock News Headlines

Warning: this could blow your mind
Buckle up… ‘Cause this might shatter everything you’ve heard about “income trading”. In fact, it’s such an extreme diversion from what most people think of typical income trades that I call it: The Perfect Income Trade You see, most of the income techniques out there target a couple of percent. Maybe 5 - 10 percent if you’re lucky. But this new way of trading income on the world’s top stocks goes after more than 10x that kind of return. And here’s the best news of all: This trade can target an opportunity like that every week. Every single week. Meaning an investor has the chance to “stack up” these more aggressive income trades over and over. If that sounds interesting…
SHOCKING Crypto Leak…
A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.
Q4 2023 X4 Pharmaceuticals Inc Earnings Call
XFOR Jan 2026 1.000 call
XFOR Apr 2024 1.500 call
X4 Pharmaceuticals Inc (XFOR)
XFOR Mar 2024 1.500 put
X4 Pharmaceuticals Inc.
XFOR May 2024 1.500 call
XFOR Jan 2025 1.500 call
XFOR Mar 2024 1.000 put
X4 Pharmaceuticals Inc XFOR
See More Headlines
Receive XFOR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for X4 Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
8/10/2023
Today
3/29/2024
Next Earnings (Estimated)
5/02/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:XFOR
Fax
N/A
Employees
93
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$3.00
High Stock Price Target
$5.00
Low Stock Price Target
$1.00
Potential Upside/Downside
+115.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
2 Analysts

Profitability

Net Income
$-101,170,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$0.31 per share

Miscellaneous

Free Float
166,124,000
Market Cap
$233.44 million
Optionable
Optionable
Beta
0.44
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives

  • Dr. Paula Ragan Ph.D. (Age 54)
    CEO, President & Director
    Comp: $963.58k
  • Mr. Adam S. MostafaMr. Adam S. Mostafa (Age 43)
    CFO, Treasurer & Corporate Secretary
    Comp: $699.18k
  • Dr. Mary DiBiase Ph.D. (Age 63)
    Chief Operating Officer
    Comp: $661.59k
  • Dr. Richard Peters M.D. (Age 61)
    Ph.D., Founder
  • Dr. Renato T. Skerlj Ph.D.
    Founder
  • Dr. Keith T. Flaherty M.D. (Age 53)
    Founder & Member of Corporate Advisory Board
  • Dr. Arthur Taveras Ph.D. (Age 60)
    Chief Scientific Officer
  • Dr. Glenn Schulman M.P.H.
    Pharm. D., Pharm.D., Vice President of Investor Relations & Corporate Communications
  • Dr. Robert David Arbeit (Age 76)
    Senior Vice President of Clinical Development and Translational Research
  • Mr. Mark Baldry M.B.A. (Age 60)
    Chief Commercial Officer

XFOR Stock Analysis - Frequently Asked Questions

Should I buy or sell X4 Pharmaceuticals stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for X4 Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" XFOR shares.
View XFOR analyst ratings
or view top-rated stocks.

What is X4 Pharmaceuticals' stock price target for 2024?

2 analysts have issued 1 year price targets for X4 Pharmaceuticals' shares. Their XFOR share price targets range from $1.00 to $5.00. On average, they anticipate the company's stock price to reach $3.00 in the next year. This suggests a possible upside of 115.8% from the stock's current price.
View analysts price targets for XFOR
or view top-rated stocks among Wall Street analysts.

How have XFOR shares performed in 2024?

X4 Pharmaceuticals' stock was trading at $0.8385 on January 1st, 2024. Since then, XFOR shares have increased by 65.8% and is now trading at $1.39.
View the best growth stocks for 2024 here
.

When is X4 Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our XFOR earnings forecast
.

How were X4 Pharmaceuticals' earnings last quarter?

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) announced its earnings results on Thursday, August, 10th. The company reported ($0.33) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.17) by $0.16. During the same period in the prior year, the business posted ($0.60) EPS.

What ETF holds X4 Pharmaceuticals' stock?

Simplify Propel Opportunities ETF holds 400,000 shares of XFOR stock, representing 0.72% of its portfolio.

What other stocks do shareholders of X4 Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other X4 Pharmaceuticals investors own include Dynavax Technologies (DVAX), Ovid Therapeutics (OVID), Pfizer (PFE), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Viking Therapeutics (VKTX), AbbVie (ABBV), Flexion Therapeutics (FLXN), Heat Biologics (HTBX) and SCYNEXIS (SCYX).

Who are X4 Pharmaceuticals' major shareholders?

X4 Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional investors include Bain Capital Life Sciences Investors LLC (10.11%), Vanguard Group Inc. (4.79%), Vanguard Group Inc. (4.79%), Kingdon Capital Management L.L.C. (2.08%), Armistice Capital LLC (1.16%) and GSA Capital Partners LLP (0.56%). Insiders that own company stock include Adam S Mostafa, Adam S Mostafa, Arthur Taveras, Derek M Meisner, Derek M Meisner, Mark Baldry, Mary Dibiase, Michael S Wyzga, Murray Stewart and Paula Ragan.
View institutional ownership trends
.

How do I buy shares of X4 Pharmaceuticals?

Shares of XFOR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:XFOR) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners